Stocks pairs trading: BMY vs MDT

BATS:MDT   Medtronic plc.
In the medical device and pharmaceutical sectors, contrasting financial metrics and market dynamics between Medtronic plc (MDT) and Bristol-Myers Squibb Company (BMY) present a compelling scenario for investors. Based on their respective financial performances and market positions, it could be strategic to consider buying BMY while contemplating selling MDT.

Reasons to Prefer BMY Over MDT:

Earnings Per Share (EPS): BMY's EPS of $3.94 is higher than MDT's $3.08. This suggests that BMY is currently more profitable and efficient in its operations compared to MDT.

Forward Price-to-Earnings (P/E) Ratio: BMY's forward P/E is significantly lower at 6.67 compared to MDT's 14.49. A lower P/E ratio often indicates that the stock is undervalued relative to its earnings potential.

Dividend Yield: BMY offers a higher dividend yield of 4.58% compared to MDT's 3.35%. This makes BMY a more attractive choice for income-focused investors.

Profit Margin: BMY has a higher profit margin of 18.44%, compared to MDT’s 12.83%. A higher profit margin typically indicates better control over costs and more efficiency in operations.

Year-to-Date Performance: Although both stocks have experienced declines, MDT's performance (-1.65% YTD) has been relatively better than BMY's significant drop (-31.87% YTD). However, BMY's lower valuation and higher dividend yield might offer a more compelling buy opportunity in anticipation of a potential rebound.


Buy 2 BMY: Given its higher profitability, attractive dividend yield, lower valuation, and potential for rebound, BMY presents a promising investment for both value and income-seeking investors.

Sell 1 MDT: Despite its stable market presence, MDT's higher valuation and lower dividend yield compared to BMY, coupled with less impressive profitability indicators, suggest that it may not offer the same level of value or income potential in the current market environment.

The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.